APA

Jamshidi A., Gharibdoost F., Vojdanian M., Soroosh S. G., Soroush M., Ahmadzadeh A., Nazarinia M. A., Mousavi M., Karimzadeh H., Shakibi M. R., Rezaieyazdi Z., Sahebari M., Hajiabbasi A., Ebrahimi A. A., Mahjourian N. & Rashti A. M. (20180417). A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. : Arthritis research & therapy.

Chicago

Jamshidi Ahmadreza, Gharibdoost Farhad, Vojdanian Mahdi, Soroosh Soosan G, Soroush Mohsen, Ahmadzadeh Arman, Nazarinia Mohammad Ali, Mousavi Mohammad, Karimzadeh Hadi, Shakibi Mohammad Reza, Rezaieyazdi Zahra, Sahebari Maryam, Hajiabbasi Asghar, Ebrahimi Ali Asghar, Mahjourian Najmeh and Rashti Amin Mohammadinejad. 20180417. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. : Arthritis research & therapy.

Harvard

Jamshidi A., Gharibdoost F., Vojdanian M., Soroosh S. G., Soroush M., Ahmadzadeh A., Nazarinia M. A., Mousavi M., Karimzadeh H., Shakibi M. R., Rezaieyazdi Z., Sahebari M., Hajiabbasi A., Ebrahimi A. A., Mahjourian N. and Rashti A. M. (20180417). A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. : Arthritis research & therapy.

MLA

Jamshidi Ahmadreza, Gharibdoost Farhad, Vojdanian Mahdi, Soroosh Soosan G, Soroush Mohsen, Ahmadzadeh Arman, Nazarinia Mohammad Ali, Mousavi Mohammad, Karimzadeh Hadi, Shakibi Mohammad Reza, Rezaieyazdi Zahra, Sahebari Maryam, Hajiabbasi Asghar, Ebrahimi Ali Asghar, Mahjourian Najmeh and Rashti Amin Mohammadinejad. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. : Arthritis research & therapy. 20180417.